Effect of Rosuvastatin in patients of Chronic Obstuctive Airway Disease and Pulmonary Hypertension

Effect of Rosuvastatin in patients of Chronic Obstuctive Airway Disease with Pulmonary Arterial Hypertension-A Randomised Prospective Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/12/003223

Enrollment

Registered

2012-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- chronic obstructive pulmonary disease with pulmonary arterial hypertension

Interventions

Intervention1: ROSUVASTATIN: a potent approved hypolipedemic agent[statin] which has pleotropic efects like antiinflamatory, vasodilatory functions. 10 mg once daily orally for 3 months Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: Patients of COPD [Criteria for diagnosis of COPD will be based on American Thoracic Society standards, with an FEV1 (forced expiratory volume in 1 second) Patients stable for at least 3 months

Exclusion criteria

Exclusion criteria: Patients with asthma, periodic wheezing,pulmonary embolism. Inability to perform 6-minute walk test Patients having liver diseases Creatinine phosphokinase (CPK) >1.5 times the normal value. Previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction. History of transient ischemic attack or stroke within 3 months. Pregnant or lactating women Bleeding disorder Patients on lipid lowering medications

Design outcomes

Primary

Measure	Time frame
effect of rosuvastatin on pulmonary arterial hypertension3Timepoint: after 3 months of treatment	—

Secondary

Measure	Time frame
effect of rosuvastatin on lung functions and quality of lifeTimepoint: after 3 months of enrolment	—

Countries

India

Contacts

Public ContactSANITHA KURIACHAN

KASTURBA MEDICAL COLLEGE

bhartimagazine@gmail.com09901728668

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026